Medtech industry gets a say in Brazil's healthcare regulatory priorities for 2013-14
This article was originally published in Clinica
Executive Summary
Medtech and pharma players in Brazil have an opportunity to comment on what and how the healthcare products regulatory agency Anvisa reviews policies and laws in areas of fundamental interest to their respective sectors over the next two years.